NCT05068323

Brief Summary

Epilepsy is a common health problem worldwide. In general population, studies in developed countries estimated the annual incidence of epilepsy to be\~50 per 100,000 and prevalence to be \~8.2 per 1,000. These figures are higher in developing countries in which prevalence of \>10 per 1,000 was reported. In Upper Egypt, Assiut Governorate, the prevalence rate was 12.9 per 1,000. In people with epilepsy there is an associated high rate of cognitive difficulties that compromise educational progress and achievement throughout life. Approximately 1-5% of the population exhibits epileptiform discharges on electroencephalography (EEG). Interictal epileptiform discharges (IEDs), meaning spikes, polyspikes, sharp waves, or spike and slow-wave complexes without observed clinical seizures, are commonly observed in patients with epilepsy. Epilepsy syndromes manifesting with IEDs are detrimental to cognitive function. Recently, two studies found that frequent IEDs can impair cognitive performance in children. and adult patients. Several studies indicated that IEDs in patients with epilepsy had a disruptive effect on information processing speed with even a low percentage of IEDs (1%).However, it is unclear whether IEDs are associated with disrupted academic performance in patients with idiopathic epilepsy, and the relationship between general cognitive ability and academic performance in those patients has not been clarified. Understanding how IEDs interfere with neurocognitive outcomes is important ,while the goal of medical and surgical treatments for epilepsy is to achieve seizure-freedom with minimal morbidity, the benefits of IED suppression are more controversial.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
98

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 20, 2021

Completed
10 days until next milestone

Study Start

First participant enrolled

September 30, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 5, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
Last Updated

October 5, 2021

Status Verified

October 1, 2021

Enrollment Period

7 months

First QC Date

September 20, 2021

Last Update Submit

October 2, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluate the effect of some High frequency epileptiform discharges measured by HZ on some cognitive domines using electroencephalogram

    2 months

Study Arms (2)

Epilepsy

OTHER

Newly diagnosed epileptic patients

Diagnostic Test: Digital electroencephalography (EEG) for an hour (16 channels)

Control

SHAM COMPARATOR

healthy subjects

Diagnostic Test: Digital electroencephalography (EEG) for an hour (16 channels)

Interventions

Digital electroencephalography (EEG) for an hour (16 channels)

ControlEpilepsy

Eligibility Criteria

Age10 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • \- a) Patients \[with age ranges from 10 to 50 years\] of both sex. b) Patients with confirmed diagnosis of idiopathic localization-related or generalized epilepsy.
  • c) Either before receiving anti-epileptic drugs or on regular treatment with antiepileptic drugs for less three months.

You may not qualify if:

  • Patients with symptomatic or secondary epilepsies either due to general medical conditions or drug induced.
  • Other neurological , psychiatric or metabolic disorders that affect cognition.
  • Regular use of antiepileptic medications more than three months.
  • utilization of regular medications other than AEDs that affect cognition.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shady Mohamed Safwat Mohamed Tawfik Hassan

Asyut, Egypt

Location

MeSH Terms

Conditions

Cognitive DysfunctionEpilepsy

Interventions

Electroencephalography

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, NeurologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Central Study Contacts

Shady Mohamed Safwat Mohamed T Hassan, MD

CONTACT

Mohamed Abdelmegid

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: case control
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Neurology

Study Record Dates

First Submitted

September 20, 2021

First Posted

October 5, 2021

Study Start

September 30, 2021

Primary Completion

May 1, 2022

Study Completion

June 1, 2022

Last Updated

October 5, 2021

Record last verified: 2021-10

Locations